Skip to main
VVOS

Vivos Therapeutics (VVOS) Stock Forecast & Price Target

Vivos Therapeutics (VVOS) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Vivos Therapeutics Inc. demonstrated significant growth during Q3 FY25, with revenues reaching $6.8 million, marking a 76% year-over-year increase and a 78% sequential rise, largely attributed to the successful integration of the Sleep Center Network (SCN). The company's service revenue more than doubled to $4.6 million, driven by substantial gains in sleep testing and treatment-center revenue, which underscores the effectiveness of the new operational model in fostering faster adoption and revenue growth. Furthermore, with a high success rate in improving conditions for patients with obstructive sleep apnea and a strong market presence in North America, alongside the expected rapid growth in the Asia Pacific region, Vivos Therapeutics is well-positioned for continued revenue expansion in the coming quarters.

Bears say

Vivos Therapeutics Inc. experienced a year-over-year revenue decline of 9% in the first half of 2025, reflecting challenges during its transition to new sleep center operations, as revenues in Q2 FY25 were $3.8 million, falling short of expectations. The company's gross margins also decreased to 55% due to discounting and changes in product and service mix, contributing to ongoing concerns about its pricing strategy and market positioning amidst competition. Additionally, Vivos faces significant operational risks, including a history of operating losses, negative cash flows, and uncertainties regarding its ability to secure capital for expansion and achieve sustainable profitability.

Vivos Therapeutics (VVOS) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vivos Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vivos Therapeutics (VVOS) Forecast

Analysts have given Vivos Therapeutics (VVOS) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Vivos Therapeutics (VVOS) has a Strong Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vivos Therapeutics (VVOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.